HSP90 and the chaperoning of cancer

Nature Reviews Cancer

Volumn 5, Issue 10, 2005, Pages 761-772

  Whitesell, Luke ^a,b   Lindquist, Susan L ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 ALLYLAMINOGELDANAMYCIN; ANSAMYCIN DERIVATIVE; BENZOQUINONE; BETA ZEARALENOL; BORTEZOMIB; CELL CYCLE PROTEIN 37; CHAPERONE; CISPLATIN; COUMAMYCIN; COUMARIN DERIVATIVE; CYTARABINE; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DEPSIPEPTIDE; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; IMMUNOPHILIN; MACROLIDE; NOVOBIOCIN; PROTEIN P23; PROTEIN P50; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; RADICICOL; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DNA BINDING; DRUG CLEARANCE; DRUG EFFICACY; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR EVOLUTION; MOLECULAR MECHANICS; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; NEOPLASMS;

EID: 25844519550     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1716     Document Type: Review

References (148)

1. Wegele, H., Muller, L. & Buchner, J. Hsp70 and Hsp90 - a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 151, 1-44 (2004).
2. Takayama, S., Reed, J. C. & Homma, S. Heat-shock proteins as regulators of apoptosis. Oncogene 22, 9041-9047 (2003).
3. Dymock, B. W., Drysdale, M. J., McDonald, E. & Workman, P. Inhibitors of HSP90 and other chaperones for the treatment of cancer. Expert. Opin. Ther. Patents 14, 837-847 (2004).
4. Morimoto, R. I. & Santoro, M. G. Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nature Biotechnol. 16, 833-838 (1998).
5. Leppa, S. & Sistonen, L. Heat shock response - pathophysiological implications. Ann. Med. 29, 73-78 (1997).
6. Jolly, C. & Morimoto, R. I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst. 92, 1564-1572 (2000).
7. Smith, D. F., Whitesell, L. & Katsanis, E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharm. Rev. 50, 493-513 (1998).
8. Buchner, J. Hsp90 & Co. - a holding for folding. Trends Biochem. Sci. 24, 136-141 (1999).
9. Csermely, P., Schnaider, T., Soti, C., Prohaskka, Z. & Nardai, G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 79, 129-168 (1998).
10. Picard, D. et al. Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature 348, 166-168 (1990).
11. Freeman, B. C. & Yamamoto, K. R. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296, 2232-2235 (2002). Surprising evidence that chaperones not only have a role in regulating the activation of signal transduction pathways, but can also modulate cellular activities by assisting in the termination of transcriptional responses.
12. Zeng, Y., Feng, H., Graner, M. W. & Katsanis, E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101, 4485-4491 (2003).
13. Parmiani, G. et al. Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res. 10, 8142-8146 (2004).
14. Smith, D. F. et al. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol. 15, 6804-6812 (1995). Describes the cyclical chaperone interactions that were shown in rabbit reticulocyte lysate to regulate the high affinity binding of hormone by steroid receptors and how this cycling is disrupted by geldanamycin.
15. Nathan, D. E., Vos, M. H. & Lindquist, S. In vivo functions of the Saccharomyces cerevisiae Hsp90 chaperone. Proc. Natl Acad. Sci. USA 94, 12949-12956 (1997).
16. Pratt, W. B. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc. Soc. Exp. Biol. Med. 217, 420-431 (1998).
17. Zhao, R. et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120, 715-727 (2005).
18. Morimoto, R. I. Dynamic remodeling of transcription complexes by molecular chaperones. Cell 110, 281-284 (2002).
19. Sollars, V. et al. Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nature Genet. 33, 70-74 (2003).
20. Sangster, T. A., Queitsch, C. & Lindquist, S. Hsp90 and chromatin: where is the link? Cell Cycle 2, 166-168 (2003).
21. Rutherford, S. L. & Lindquist, S. Hsp90 as a capacitor for morphological evolution. Nature 396, 336-342 (1998). Groundbreaking report that the chaperone function of HSP90 can buffer genetic variation in D. melanogaster, allowing it to accumulate silently until it is released in the face of environmental stress to be acted on by natural selection.
22. Queitsch, C., Sangster, T. A. & Lindquist, S. Hsp90 as a capacitor of phenotypic variation. Nature 417, 618-624 (2002).
23. Ruden, D. M., Garfinkel, M. D., Sollars, V. E. & Lu, X. Waddington's widget: Hsp90 and the inheritance of acquired characters. Semin. Cell Dev. Biol. 14, 301-310 (2003).
24. Sangster, T. A., Lindquist, S. & Queitsch, C. Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays 26, 348-362 (2004).
25. Rutherford, S. L. Between genotype and phenotype: protein chaperones and evolvability. Nature Rev. Genet. 4, 263-274 (2003).
26. Bagatell, R. & Whitesell, L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. 3, 1021-1030 (2004).
27. Gatenby R. A. & Vincent, T. L. An evolutionary model of carcinogenesis. Cancer Res. 63, 6212-6220 (2003).
28. Kimura, E. et al. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60kDa heat shock protein Hsp60. J. Clin. Oncol. 11, 891-898 (1993).
29. Ciocca, D. R. et al. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J. Natl Cancer Inst. 85, 570-574 (1993).
30. Conroy, S. E., Sasieni, P. D., Fentiman, I. & Latchman, D. S. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. Eur. J. Cancer 34, 942-943 (1998).
31. Ralhan, R. & Kaur, J. Differential expression of Mr 70, 000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin. Cancer Res. 1, 1217-1222 (1995).
32. Kaur, J. & Ralhan, R. Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis. Int. J. Cancer 63, 774-779 (1995).
33. Santarosa, M., Favaro, D., Quaia, M. & Galligioni, E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Euro. J. Cancer. 33, 873-877 (1997).
34. Chant, I. D., Rose, P. E. & Morris, A. G. Analysis of heat shock protein expression in myeloid leukaemia cells by flow cytometry. Br. J. Haematol. 90, 163-168 (1995).
35. Yufu, Y., Nishimura, J. & Nawata, H. High constitutive expression of heat shock protein 90α in human acute leukemia cells. Leuk. Res. 16, 597-605 (1992).
36. Jameel, A. et al. Clinical and biological significance of Hsp90a in human breast cancer. Int. J. Cancer 50, 409-415 (1992).
37. Yano, M., Naito, Z., Tanaka, S. & Asano, G. Expression and roles of heat shock proteins in human breast cancer. Jpn. J. Cancer Res. 87, 908-915 (1996).
38. Nanbu, K. et al. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detection & Prevention. 22, 549-555 (1998).
39. Trieb, K. et al. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br. J. Cancer 82, 85-87 (2000).
40. Mosser, D. D. & Morimoto, R. I. Molecular chaperones and the stress of oncogenesis. Oncogene 23, 2907-2918 (2004).
41. Jaattela, M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 248, 30-43 (1999).
42. Hannun, Y. Apoptosis and the dilemma of cancer chemotherapy. Blood 89, 1845-1853 (1997).
43. Sliutz, G. et al. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br. J. Cancer 74, 172-177 (1996).
44. Mosser, D. D. et al. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol. Cell. Biol. 20, 7146-7159 (2000).
45. Steel, R. et al. et al. Hsp72 inhibits apoptosis upstream of the mitochondria and not through interactions with Apaf-1. J. Biol. Chem. 279, 51490-51499 (2004).
46. Mosser, D. D., Caron, A. W., Bourget, L., Denis-Larose, C. & Massie, B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol. Cell. Biol. 17, 5317-5327 (1997).
47. Nylandsted, J. et al. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc. Natl Acad. Sci. USA 97, 7871-7876 (2000). Demonstrates differential requirements for HSP70 in the growth and survival of breast cancer cells compared with normal cells.
48. Rohde, M. et al. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev. 19, 570-582 (2005).
49. Basso, A. D. et al. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 277, 39858-39866 (2002).
50. Vanden Berghe, T., Kalai, M., van Loo, G., Declercq, W. & Vandenabeele, P. Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis. J. Biol. Chem. 278, 5622-5629 (2003).
51. Chen, G., Cao, P. & Goeddel, D. V. TNF-induced recruitment and activation of the IκK complex require Cdc37 and Hsp90. Mol. Cell 9, 401-410 (2002).
52. Xu, Y., Singer, M. A. & Lindquist, S. Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc. Natl Acad. Sci. USA 96, 109-114 (1999).
53. Oppermann, H., Levinson, W. & Bishop, J. M. A cellular protein that associates with the transforming protein of Rous sarcoma virus is also a heat-shock protein. Proc. Natl Acad. Sci. USA 78, 1067-1071 (1981).
54. Brugge, J., Yonemoto, W. & Darrow, D. Interaction between the Rous sarcoma virus transforming protein and two cellular phosphoproteins: analysis of the turnover and distribution of this complex. Mol. Cell. Biol. 3, 9-19 (1983).
55. Xu, Y. & Lindquist, S. Heat-shock protein hsp90 governs the activity of pp60vsrc kinase. Proc. Natl Acad. Sci. USA 90, 7074-7078 (1993).
56. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E. & Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91, 8324-8328 (1994). Identification of geldanamycin as the first small-molecule inhibitor of HSP90 chaperone function.
57. Muller, L., Schaupp, A., Walerych, D., Wegele, H. & Buchner, J. Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J. Biol. Chem. 279, 48846-48854 (2004).
58. Walerych, D. et al. Hsp90 chaperones wild-type p53 tumor suppressor protein. J. Biol. Chem. 279, 48836-48845 (2004).
59. Whitesell, L., Sutphin, P. D., Pulcini, E. J., Martinez, J. D. & Cook, P. H. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol. 18, 1517-1524 (1998).
60. Blagosklonny, M. V., Toretsky, J., Bohen, S. & Neckers, L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl Acad. Sci. USA 93, 8379-8383 (1996).
61. Sepehrnia, B., Paz, I. B., Dasgupta, G. & Momand, J. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J. Biol. Chem. 271, 15084-15090 (1996).
62. Sreedhar, A. S., Kalmar, E., Csermely, P. & Shen, Y. F. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 562, 11-15 (2004).
63. Eustace, B. K. et al. Functional proteomic screens reveal an essential extracellular role for hsp90 α in cancer cell invasiveness. Nature Cell Biol. 6, 507-514 (2004).
64. Grammatikakis, N. et al. The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J. Biol. Chem. 277, 8312-8320 (2002).
65. Pearl, L. H. & Prodromou, C. Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv. Protein Chem. 59, 157-186 (2001).
66. Prodromou, C. & Pearl, L. H. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 3, 301-323 (2003).
67. Stebbins, C. E. et al. Crystal structure of an hsp90-geldanamycin complex: targeting of a protein chaperone by an anti-tumor agent. Cell 89, 239-250 (1997).
68. Prodromou, C. et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90, 65-75 (1997). Identification and characterization of the binding pocket for geldanamycin on HSP90 as an atypical ATPase site.
69. Meyer, P. et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol. Cell 11, 647-658 (2003).
70. Huai, Q. et al. Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure (Camb) 13, 579-590 (2005).
71. Harris, S. F., Shiau, A. K. & Agard, D. A. The crystal structure of the carboxy-terminal dimerization domain of htpG, the Escherichia coli Hsp90, reveals a potential substrate binding site. Structure (Camb) 12, 1087-1097 (2004).
72. Dutta, R. & Inouye, M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 25, 24-28 (2000).
73. McLaughlin, S. H., Ventouras, L. A., Lobbezoo, B. & Jackson, S. E. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. J. Mol. Biol. 344, 813-826 (2004). Biophysical evidence for an alternative to the 'molecular clamp' model of HSP90 chaperoning action.
74. Roe, S. M. et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116, 87-98 (2004).
75. Pearl, L. H. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 15, 55-61 (2005).
76. Soti, C., Racz, A. & Csermely, P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. J. Biol. Chem. 277, 7066-7075 (2002).
77. Meyer, P. et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. Embo J. 3, 511-519 (2004).
78. Panaretou, B. et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell 10, 1307-1318 (2002).
79. Garnier, C. et al. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J. Biol. Chem. 277, 12208-12214 (2002).
80. Scheufler, C. et al. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 101, 199-210 (2000). Structural elucidation of how multichaperone complexes can be formed by adapter proteins.
81. Prodromou, C. et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. Embo J. 18, 754-762 (1999).
82. Lee, Y. S., Marcu, M. G. & Neckers, L. Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin. Chem. Biol. 11, 991-998 (2004).
83. Roe, S. M. et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42, 260-266 (1999).
84. Xu, W. et al. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl Acad. Sci. USA 99, 12847-12852 (2002). Identification of a mechanism by which chaperone interactions regulate the cellular level of a receptor-linked tyrosine kinase.
85. Nathan, D. F. & Lindquist, S. Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase. Mol. Cell. Biol. 15, 3917-3925 (1995).
86. Birnby, D. A. et al. A transmembrane guanylyl cyclase (DAF-11) and Hsp90 (DAF-21) regulate a common set of chemosensory behaviors in Caenorhabditis elegans. Genetics 155, 85-104 (2000).
87. Yue, L. et al. Genetic analysis of viable Hsp90 alleles reveals a critical role in Drosophila spermatogenesis. Genetics 151, 1065-1079 (1999).
88. LeBlanc, R. et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000 (2002).
89. Kim, J. et al. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J. Biomol. Screen. 9, 375-381 (2004).
90. Kamal, A., Boehm, M. F. & Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 10, 283-290 (2004).
91. Kamal, A. et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410 (2003). First evidence that HSP90 in tumour cells is found in multimolecular complexes with higher affinity for 17AAG than the largely uncomplexed HSP90 found in normal cells. This paper provides a biochemical explanation for why a useful therapeutic index might exist for HSP90 inhibitors.
92. Workman, P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 10, 47-51 (2004).
93. Yun, B. G., Huang, W., Leach, N., Hartson, S. D. & Matts, R. L. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 43, 8217-8229 (2004).
94. Marcu, M. G., Schulte, T. W. & Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl Cancer Inst. 92, 242-248 (2000).
95. Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M. & Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the C-terminus of the chaperone. J. Biol. Chem. 275, 37181-37186 (2000). Biochemical evidence for a second, cryptic ATP-binding site in HSP90 that binds the antibiotic novobiocin, albeit with very low affinity.
96. Itoh, H. et al. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem. J. 343, 697-703 (1999).
97. Rosenhagen, M. C. et al. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol. Endocrinol. 17, 1991-2001 (2003).
98. McIlwrath, A. J., Brunton, V. G. & Brown, R. Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer Chemother. Pharmacol. 37, 423-428 (1996).
99. Nomura, M. et al. Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells. J. Cell. Physiol. 201, 374-384 (2004).
100. Srethapakdi, M., Liu, F., Tavorath, R. & Rosen, N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. 60, 3940-3946 (2000).
101. Hostein, I., Robertson, D., DiStefano, F., Workman, P. & Clarke, P. A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61, 4003-4009 (2001).
102. Bagatell, R., Beliakoff, J., David, C. L., Marron, M. T. & Whitesell, L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int. J. Cancer 113, 179-188 (2005).
103. Munster, P. N., Basso, A., Solit, D., Norton, L. & Rosen, N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner.
104. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res. 7, 2155-2158 (2001).
105. Clin. Cancer Res. 7, 2228-2236 (2001). Evidence for the ability of HSP90 inhibitors to increase the anticancer activity of cytotoxic chemotherapeutic agents.
106. Basso, A. D., Solit, D. B., Munster, P. N. & Rosen, N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21, 1159-1166 (2002).
107. Maloney, A., Clarke, P. A. & Workman, P. Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr. Cancer Drug Targets 3, 331-341 (2003).
108. Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N. & Sawyers, C. L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100, 3041-3044 (2002). Clinical BCR-ABL mutations that render the kinase resistant to the active site inhibitor imatinib (Glivec) remain HSP90-dependent and, as a result, quite sensitive to geldanamycin-stimulated degradation. Such a lack of cross-resistance provides the rationale for current clinical studies of 17AAG in imatinib-resistant patients.
109. Bonvini, P., Dalla Rosa, H., Vignes, N. & Rosolen, A. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res. 64, 3256-3264 (2004).
110. Beliakoff, J. et al. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin. Cancer Res. 9, 4961-4971 (2003).
111. Solit, D. B. et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/NEU and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8, 986-993 (2002).
112. Munster, P. N., Marchion, D. C., Basso, A. D. & Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res. 62, 3132-3137 (2002).
113. Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I. & Rosen, N. Inhibition of heat shock protein 90 function down-regulates akt kinase and sensitizes tumors to taxol. Cancer Res. 63, 2139-2144 (2003).
114. Bagatell, R. et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90 binding agents. Clin. Cancer Res. 6, 3312-3318 (2000).
115. Clarke, P. A. et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17- demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene. 19, 4125-4133 (2000).
116. Burger, A. M., Fiebig, H. H., Stinson, S. F. & Sausville, E. A. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15, 377-387 (2004).
117. Lu, A., Ran, R., Parmentier-Batteur, S., Nee, A. & Sharp, F. R. Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J. Neurochem. 81, 355-364 (2002).
118. Sittler, A. et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10, 1307-1315 (2001).
119. Auluck, P. K., Meulener, M. C. & Bonini, N. M. Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in Drosophila. J. Biol. Chem. 280, 2873-2878 (2005).
120. Egorin, M. J. et al. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother. Pharmacol. 47, 291-302 (2001).
121. Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G. & Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst. 91, 1940-1949 (1999).
122. Goetz, M. P. et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 23, 1078-1087 (2005).
123. Rajkumar, S. V., Richardson, P. G., Hideshima, T. & Anderson, K. C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630-639 (2005).
124. Grem, J. L. et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 23, 1885-1893 (2005).
125. Banerji, U. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23, 4152-4161 (2005). Report of a phase I trial of 17AAG demonstrating the modulation of HSP90 function by systemically tolerable drug exposures and the stabilization of disease in two melanoma patients.
126. Enmon, R. et al. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res. 63, 8393-8399 (2003).
127. Bisht, K. S. et al. Geldanamycin and 17-allylamino-17- demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 63, 8984-8995 (2003).
128. McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
129. Vasilevskaya, I. A., Rakitina, T. V. & O'Dwyer, P. J. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res. 63, 3241-3246 (2003).
130. Mimnaugh, E. G. et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol. Cancer Ther. 3, 551-566 (2004).
131. Mitsiades, C. S., Mitsiades, N., Richardson, P. G., Treon, S. P. & Anderson, K. C. Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin. Oncol. 30, 309-312 (2003).
132. Rahmani, M. et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. 63, 8420-8427 (2003).
133. Yu, X. et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94, 504-513 (2002).
134. Dymock, B. et al. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 14, 325-328 (2004).
135. Chiosis, G., Lucas, B., Shtil, A., Huezo, H. & Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10, 3555-3564 (2002).
136. Rowlands, M. G. et al. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem. 327, 176-183 (2004).
137. Turbyville, T. J., Wijeratne, E. M. K., Whitesell, L. & Gunatilaka, A. A. L. The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways. Mol. Cancer Ther. (in the press).
138. Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
139. Kuduk, S. D. et al. Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg. Med. Chem. Lett. 10, 1303-1306 (2000).
140. Zheng, F. F. et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 60, 2090-2094 (2000).
141. Patel, K. et al. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Chem. Biol. 11, 1625-1633 (2004).
142. Soga, S. et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 59, 2931-2938 (1999).
143. Eiseman, J. L. et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C. B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 55, 21-32 (2005).
144. Schulte, T. W. et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the RAF-1-MEK-mitogen-activated protein kinase signalling pathway. Mol. Cell. Biol. 16, 5839-5845 (1996).
145. Stepanova, L., Leng, X., Parker, S. B. & Harper, J. W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Devel. 10, 1491-1502 (1996).
146. Holt, S. E. et al. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Devel. 13, 817-824 (1999).
147. Isaacs, J. S. et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway. J. Biol. Chem. 277, 29936-29944 (2002).
148. Falsone, F. M., Leptihn, S., Osterauer, A., Haslbeck, M. & Buchner, J. Oncogenic mutations reduce the stability of Src kinase. J. Mol. Biol. 344, 281-291 (2004).